Manual urine collection contaminates 3 in 10 diagnostic samples. CleverCUP is a single-use, anatomy-aligned device that separates first-void urine from the clean midstream automatically — eliminating diagnostic errors at the source.
Correct midstream collection asks a patient to part labia with one hand, clean, then pee a small amount in the commode, hold, aim and give midstream sample in the universal urine collector, without guidance. Most don't get it right.
CleverCUP uses a fluidic pathway — not electronics — to route each stage of the void into its own chamber, in the order it's produced. No stopping, repositioning, or manual timing required; just use and seal.
The initial ~10ml, carrying skin and perineal contaminants, fills a dedicated compartment and locks in place via the ball-float valve.
Once the valve locks, clean midstream flow diverts automatically into a separate sterile chamber — ready for culture and sensitivity testing.
A third compartment captures late-stream flow, enabling full urine-profile analysis — useful for urinary bladder microbiome analysis.
Four stages from first hand-drawn sketch to a validated, TRL 4 device — same funnel-and-valve concept, refined through every iteration.
To cater the four distinct care settings from the single technology.
Manages the entire void in privacy curtains for PHCs and rural health camps with no fixed restroom.
Palm-sized, ergonomic design built for urban diagnostic chains and standard home bathrooms.
30-second real-time screening for seamless sample triaging, effective urine culture and AST of dipstick positives only.
Mechanism is optimised for cardiometabolic disease screening and monitoring — improved ACR efficiency.
The market is built bottom-up from the ~60,000 registered hospitals already prescribing urine culture tests to UTI-suspected patients.
36 lakh tests/day × 264 working days, at a tentative ₹50 unit price.
Share of TAM addressable through women's UTI screening alone.
Of SAM targeted as the realistic serviceable segment.
Potential revenue at 10% capture of SOM within three years.
Proof-of-principle was established through in-vitro testing with artificial urine spiked with known uropathogens, followed by clinician and patient surveys.
A chronological record of the milestones, foundation days, and exhibition floors that have shaped CleverCUP since its first public showing in November 2024.
CleverCUP named a Race-from-Science-to-Entrepreneurship winner at the 1st Foundation Day of BRIC, Department of Biotechnology — guest of honour Shri Amitabh Kant, G20 Sherpa & former CEO, NITI Aayog.
Honoured at the 39th Foundation Day of the Department of Biotechnology, with a ₹1 lakh award from Dr. Anand Deshpande, Founder & Chairman of Persistent Systems, to support project development.
Gold Award and a ₹1 lakh prize at the Medicall Healthcare Innovation Awards 2025, Medicall Expo Chennai — hosted by Bio Vedas and Anna University.
First prize (₹75,000) in the SSD category of TechX at IKMC'25, hosted by IKP Knowledge Park.
CleverCUP's public debut at booth 27 — the first time visitors outside the lab could see, hold, and ask questions about the device.
At SINE, IIT Bombay — this time with Aura, Urban, Triage, and Omni all on display side by side.
Presenting CleverCUP Aura to the institute that helped build it — from a Biodesign Fellowship prototype to a platform with four variants in the field.
Imported midstream devices run ₹200–₹450. CleverCUP targets ₹20–25 per unit for B2B and ₹50 retail, with an ex-factory cost of ₹8–10 at scale.
Integrates into RMNCH+A, maternal care, and school-based screening under existing government health infrastructure.
Institutional supply to PHCs, telemedicine labs, NGOs, and diagnostic networks, reducing repeat-test costs from contamination.
Available through pharmacies and e-commerce for home use, with dignity-first design for women, elderly men, and children.
Incorporated in 2025 and based in Delhi NCR, developing diagnostic-grade collection devices under the SIB Biodesign Fellowship at BRIC-THSTI, with clinical advisors from PGIMER Chandigarh and ESIC Faridabad.
We're onboarding pilot sites, institutional partners, and distribution channels ahead of CDSCO approval and commercial scale-up, backed by BFI m-Pragati IIT Delhi, DBT-BRIC-THSTI, and RCB BBB.